A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
about
Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates.Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brainGlutamatergic drugs for schizophreniaPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature reviewAutoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implicationsStructural and Functional Analysis of Two New Positive Allosteric Modulators of GluA2 Desensitization and DeactivationStructural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domainMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaAmpakines alleviate respiratory depression in ratsGlutamate receptor ion channels: structure, regulation, and functionAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacyMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.Research in people with psychosis risk syndrome: a review of the current evidence and future directionsMolecular targets for treating cognitive dysfunction in schizophrenia.Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.Neuroacanthocytosis associated with a defect of the 4.1R membrane proteinElevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia.Challenges for and current status of research into positive modulators of AMPA receptors.Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats.A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteersNewer molecules in the treatment of schizophrenia: A clinical updateRestoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factorEmerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.The search for novel antipsychotics: pharmacological and molecular targets.Autism spectrum disorders: emerging pharmacotherapy.AMPA receptors and stargazin-like transmembrane AMPA receptor-regulatory proteins mediate hippocampal kainate neurotoxicity.Glutamate modulators as novel interventions for mood disorders.Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.Neuroprotective agents in schizophrenia and affective disorders.Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networksRole of glutamate in schizophrenia: integrating excitatory avenues of research.Synaptic regulation of affective behaviors; role of BDNFA potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder.Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Re-conceptualizing ASD Within a Dimensional Framework: Positive, Negative, and Cognitive Feature Clusters.The treatment of cognitive impairment in schizophrenia.
P2860
Q21092790-D9FC6E4E-14E9-4C16-85B2-C67969D57DB4Q21129314-F7802E91-CE76-455B-AB88-E11B7D471723Q24246163-53C4BC9E-DC9D-4C98-9EEA-FB9697494E18Q24598636-B6C10A93-51E9-4B67-BC4B-B6145BAA9286Q26775915-2F5A019A-88B0-40FC-91E2-3CF6BF0A35A4Q27667701-B5F104EB-98F4-4C94-8AE1-A4B369A42643Q27685440-EAFBB6DE-0B2E-421D-9F78-176C45612818Q28248687-D8D00647-B335-48B3-9AEC-4E3D7EEAE03EQ28263792-29BDCE87-66B3-4B13-BAD7-2FB637E7650FQ28290774-903A1BF3-E6F8-4B74-92DC-80F6C1DB5325Q28297813-7D84FC57-0B04-48DA-8FA9-1CDF9BDBF90EQ30428213-B33F71D3-80BC-4ACD-A676-5FA37E3672B7Q30475598-57BCD660-FD30-4A32-B8D3-DA50C781EF78Q30491310-A389BD14-D254-44DD-82D2-03587A8C3331Q30977943-1A23DD8E-38D5-4567-A122-90376E34CB21Q33273711-637F43D1-E5E2-4620-82E6-29E3C694033EQ33302991-0599B6B9-A2D6-4826-95D7-1538F89098FAQ33870362-0839CFA7-383E-4031-84D2-88EFBD6A7972Q34190402-BB045BF7-66B2-4C47-99C3-8E33D0C9DBCDQ34230984-D8BE8155-6ED3-4592-80E5-8E9D0AFBC2A9Q34300194-8DCC2228-EBEE-46AB-B807-4E7AF87C93B3Q34579324-FC460719-84AA-464E-B1F7-1534CAB20EBEQ34726039-408E1D84-E0FE-4A84-AC87-48333FE37080Q34843883-191C9634-BF29-4CF7-8AF5-0D8B9E36B85AQ35008236-104239D3-2DA2-4DF0-AE77-5B6206C1886BQ35770190-30A92EB1-4E56-4795-AF55-D3B3FEA865C0Q35976379-07CEAE6E-DB11-40E3-AF8A-48B3A980E171Q36219642-E5383DF2-0642-45A9-8136-5432DD1C858EQ36277019-25285A44-C9FC-48B1-AEF1-D44600B38DD9Q36285982-1C2DD4A9-0728-4AEB-A854-0238CA7CD958Q36302850-CDB9E07D-7DDB-4BEB-8CB5-738C61406678Q36458436-A70588F2-E5E9-40B7-8CCB-F307CACF7CD0Q36886717-E17092FE-D0B4-4E26-A1FA-5BAFDEA23BC6Q37220392-E46C051C-D53D-449C-A19D-40EE857D1C9BQ37256709-67BFBC66-0D14-4E58-A375-1ADD63598AB7Q37302923-41564BBE-5938-4146-9100-72E59020F063Q37395509-9EA599C8-1708-4190-A462-E9385D34FBBCQ37662441-810A8396-D286-4A16-AFBC-6BB1FEBF6FF4Q37670079-DBB05840-379A-4F74-997E-B6ACEEE62D59Q37813206-47FD89E6-3D41-448E-B5EF-B14BDE5479CF
P2860
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@ast
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@en
type
label
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@ast
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@en
prefLabel
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@ast
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@en
P2093
P1476
A placebo-controlled pilot stu ...... to clozapine in schizophrenia.
@en
P2093
Johnson SA
P304
P356
10.1097/00004714-200110000-00005
P407
P577
2001-10-01T00:00:00Z